{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,16]],"date-time":"2026-09-16T19:30:14Z","timestamp":1789587014986,"version":"build-2803163510"},"reference-count":127,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2025,11,6]],"date-time":"2025-11-06T00:00:00Z","timestamp":1762387200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,11,6]],"date-time":"2025-11-06T00:00:00Z","timestamp":1762387200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Medizinische Hochschule Hannover (MHH)"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Naunyn-Schmiedeberg's Arch Pharmacol"],"published-print":{"date-parts":[[2026,2]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>\n                    G protein-coupled receptors (GPCRs) are often stated to constitute the target of 30% (or even more) of all approved drugs. This number, probably first mentioned in (\n                    <jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" xlink:href=\"https:\/\/pubmed.ncbi.nlm.nih.gov\/12209152\/\" ext-link-type=\"uri\">https:\/\/pubmed.ncbi.nlm.nih.gov\/12209152\/<\/jats:ext-link>\n                    ) and later has been\u00a0often cited by many other studies and in some studies even taken for granted, but is this true? In this study, the number of approved drugs acting on GPCRs was analyzed in relation to the total number of approved drugs in Germany. Newly approved drugs in the years 1987\u20132023 were analyzed. Of the newly approved drugs in Germany in this period, 209 out of 1110 drugs (19%) act primarily on GPCRs. The most common drug target during this period were enzymes (mostly inhibitors), followed by receptor agonists and antagonists. Among all receptor classes, GPCRs are the most common drug target. In recent years, there has been an increase in antibody approvals, making them the fourth most common drug class in the time from 1987\u20132023. For the years 1999\/2000, 2002 and 2023, all drugs listed in the WHO Model List of Essential Medicines were examined regarding targeting GPCRs. In none of the years do more than 15% of the drugs act on GPCRs. 63 of 293 drugs (22%)  of\u00a0the drug list (version 1.0) and 103 of 464 (22%)  of\u00a0version 2.0 of the Institut f\u00fcr Medizinische und Pharmazeutische Pr\u00fcfungsfragen (Institute for Medical and Pharmaceutical Review Questions) in Germany were identified as GPCR drugs. All drugs  of\u00a0the Rote Liste (Red List) from 2002 and 2023 were examined regarding targeting GPCRs, resulting in a share of 20%. The frequently cited 30% in the drug studies conducted to date mostly refers to FDA-approved drugs. Therefore, the proportion of GPCR-mediated FDA approved drugs does not match the newly approved drugs in Germany or other analyzed sources. This study sends a note of caution to researchers when using data without further specification or precise context in the literature. Such numbers should be analyzed critically and not taken for granted in every situation.\n                  <\/jats:p>","DOI":"10.1007\/s00210-025-04548-3","type":"journal-article","created":{"date-parts":[[2025,11,6]],"date-time":"2025-11-06T08:27:46Z","timestamp":1762417666000},"page":"5575-5604","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Do GPCRs constitute the target of 30% of newly approved drugs in Germany?"],"prefix":"10.1007","volume":"399","author":[{"given":"Sophia","family":"Schr\u00f6er","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roland","family":"Seifert","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,11,6]]},"reference":[{"key":"4548_CR1","unstructured":"Aerzteblatt.de. (2022). New receptor binding sites for GPCR-targeted drugs discovered. https:\/\/www.aerzteblatt.de\/nachrichten\/134165\/Neue-Rezeptorindungsstellen-fuer-GPCR-gerichtete-Medikamente-entdeckt, last accessed 23.09.2024."},{"key":"4548_CR2","unstructured":"Alberts, B., Hopkin, K., Johnson, A., Morgan, D., Raff, M., Roberts, K., and Walter, P. (2019). Essential cell biology. Fifth edition. (New York; London: W. W. Norton & Company)."},{"key":"4548_CR3","unstructured":"Sunny Al-Shamma, President and CEO Beacon Discovery. Nature research (https:\/\/www.nature.com\/articles\/d43747-020-01094-0, last accessed 23.09.2024)"},{"key":"4548_CR4","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-023-36855-1","volume":"13","author":"M Amer","year":"2023","unstructured":"Amer M, Leka O, Jasko P, Frey D, Li X, Kammerer RA (2023) A coiled-coil-based design strategy for the thermostabilization of G-protein-coupled receptors. Sci Rep 13:10159. https:\/\/doi.org\/10.1038\/s41598-023-36855-1","journal-title":"Sci Rep"},{"key":"4548_CR5","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-023-35790-z","volume":"14","author":"S Anantakrishnan","year":"2023","unstructured":"Anantakrishnan S, Naganathan AN (2023) Thermodynamic architecture and conformational plasticity of GPCRs. Nat Commun 14:128. https:\/\/doi.org\/10.1038\/s41467-023-35790-z","journal-title":"Nat Commun"},{"key":"4548_CR6","doi-asserted-by":"publisher","first-page":"169","DOI":"10.1016\/j.ejphar.2018.03.003","volume":"826","author":"MA Ayoub","year":"2018","unstructured":"Ayoub MA (2018) Small molecules targeting heterotrimeric G proteins. Eur J Pharmacol 826:169\u2013178. https:\/\/doi.org\/10.1016\/j.ejphar.2018.03.003","journal-title":"Eur J Pharmacol"},{"key":"4548_CR7","doi-asserted-by":"publisher","first-page":"27497","DOI":"10.1074\/jbc.272.44.27497","volume":"272","author":"LS Barak","year":"1997","unstructured":"Barak LS, Ferguson SSG, Zhang J, Caron MG (1997) A \u03b2-arrestin\/green fluorescent protein biosensor for detecting G protein-coupled receptor activation*. J Biol Chem 272:27497\u201327500. https:\/\/doi.org\/10.1074\/jbc.272.44.27497","journal-title":"J Biol Chem"},{"key":"4548_CR8","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-022-30570-7","volume":"13","author":"BDM Bean","year":"2022","unstructured":"Bean BDM, Mulvihill CJ, Garge RK, Boutz DR, Rousseau O, Floyd BM, Cheney W, Gardner EC, Ellington AD, Marcotte EM, Gollihar JD, Whiteway M, Martin VJJ (2022) Functional expression of opioid receptors and other human GPCRs in yeast engineered to produce human sterols. Nat Commun 13:2882. https:\/\/doi.org\/10.1038\/s41467-022-30570-7","journal-title":"Nat Commun"},{"key":"4548_CR9","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-019-11875-6","volume":"10","author":"B Benredjem","year":"2019","unstructured":"Benredjem B, Gallion J, Pelletier D, Dallaire P, Charbonneau J, Cawkill D, Nagi K, Gosink M, Lukasheva V, Jenkinson S, Ren Y, Somps C, Murat B, Van Der Westhuizen E, Le Gouill C, Lichtarge O, Schmidt A, Bouvier M, Pineyro G (2019) Exploring use of unsupervised clustering to associate signaling profiles of GPCR ligands to clinical response. Nat Commun 10:4075. https:\/\/doi.org\/10.1038\/s41467-019-11875-6","journal-title":"Nat Commun"},{"key":"4548_CR10","doi-asserted-by":"publisher","first-page":"293","DOI":"10.2174\/1570163816666191202104315","volume":"18","author":"A Bedair","year":"2021","unstructured":"Bedair A, Mansour FR (2021) Insights into the FDA 2018 New Drug Approvals. Curr Drug Discov Technol 18:293\u2013306. https:\/\/doi.org\/10.2174\/1570163816666191202104315","journal-title":"Curr Drug Discov Technol"},{"key":"4548_CR11","unstructured":"Bermudez Sasso, M. (2015). Structural Basis for Tailor-Made Modulation of G Protein Coupled Receptor Functionality, https:\/\/refubium.fu-berlin.de\/handle\/fub188\/5859, last accessed 23.09.2024."},{"key":"4548_CR12","doi-asserted-by":"publisher","unstructured":"Beyond on or off. Nat Chem Biol 15, 1 (2019). https:\/\/doi.org\/10.1038\/s41589-018-0202-5. https:\/\/www.nature.com\/articles\/s41589-018-0202-5#rightslink, last accessed 23.09.2024.","DOI":"10.1038\/s41589-018-0202-5"},{"key":"4548_CR13","doi-asserted-by":"publisher","first-page":"7408","DOI":"10.1038\/s41467-022-35069-9","volume":"13","author":"E Bielczyk-Maczynska","year":"2022","unstructured":"Bielczyk-Maczynska E, Zhao M, Zushin PH, Schnurr TM, Kim H, Li J, Nallagatla P, Sangwung P, Park CY, Cornn C, Stahl A, Svensson KJ, Knowles JW (2022) G protein-coupled receptor 151 regulates glucose metabolism and hepatic gluconeogenesis. Nat Commun 13:7408. https:\/\/doi.org\/10.1038\/s41467-022-35069-9","journal-title":"Nat Commun"},{"key":"4548_CR14","doi-asserted-by":"publisher","first-page":"255","DOI":"10.3389\/fphar.2014.00255","volume":"5","author":"S Brogi","year":"2014","unstructured":"Brogi S, Tafi A, D\u00e9saubry L, Nebigil CG (2014) Discovery of GPCR ligands for probing signal transduction pathways. Front Pharmacol 5:255. https:\/\/doi.org\/10.3389\/fphar.2014.00255","journal-title":"Front Pharmacol"},{"key":"4548_CR15","doi-asserted-by":"publisher","first-page":"1457","DOI":"10.1186\/s12913-022-08866-7","volume":"22","author":"M B\u00fcssgen","year":"2022","unstructured":"B\u00fcssgen M, Stargardt T (2022) Changes in launch delay and availability of pharmaceuticals in 30 European markets over the past two decades. BMC Health Serv Res 22:1457\u20131467. https:\/\/doi.org\/10.1186\/s12913-022-08866-7","journal-title":"BMC Health Serv Res"},{"key":"4548_CR16","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1016\/j.beem.2018.01.004","volume":"32","author":"D Calebiro","year":"2018","unstructured":"Calebiro D, Godbole A (2018) Internalization of G-protein-coupled receptors: implication in receptor function, physiology and diseases. Best Pract Res Clin Endocrinol Metab 32:83\u201391. https:\/\/doi.org\/10.1016\/j.beem.2018.01.004","journal-title":"Best Pract Res Clin Endocrinol Metab"},{"key":"4548_CR17","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1016\/j.cell.2020.03.003","volume":"181","author":"M Congreve","year":"2020","unstructured":"Congreve M, de Graaf C, Swain NA, Tate CG (2020) Impact of GPCR structures on drug discovery. Cell 181:81\u201391. https:\/\/doi.org\/10.1016\/j.cell.2020.03.003","journal-title":"Cell"},{"key":"4548_CR18","doi-asserted-by":"publisher","first-page":"1006","DOI":"10.1016\/j.tips.2020.10.001","volume":"41","author":"AC Cornwell","year":"2020","unstructured":"Cornwell AC, Feigin ME (2020) Unintended effects of GPCR-targeted drugs on the cancer phenotype. Trends Pharmacol Sci 41:1006\u20131022. https:\/\/doi.org\/10.1016\/j.tips.2020.10.001","journal-title":"Trends Pharmacol Sci"},{"key":"4548_CR19","doi-asserted-by":"publisher","unstructured":"Dahl, Kotliar, Bendes, Dodig-Crnkovi\u0107&nbsp, Fromm, Elofsson, Uhl\u00e9n&nbsp, Sakmar, and Schwenk. Multiplexed selectivity screening of anti-GPCR antibodies. Sci. Adv. 9, eadf9297. https:\/\/doi.org\/10.1126\/sciadv.adf9297.","DOI":"10.1126\/sciadv.adf9297"},{"key":"4548_CR20","doi-asserted-by":"publisher","first-page":"6439","DOI":"10.1038\/s41467-023-42082-z","volume":"14","author":"D Di Marino","year":"2023","unstructured":"Di Marino D, Conflitti P, Motta S, Limongelli V (2023) Structural basis of dimerization of chemokine receptors CCR5 and CXCR4. Nat Commun 14:6439. https:\/\/doi.org\/10.1038\/s41467-023-42082-z","journal-title":"Nat Commun"},{"key":"4548_CR21","doi-asserted-by":"publisher","first-page":"214","DOI":"10.1016\/j.ejphar.2015.05.016","volume":"763","author":"NM Duc","year":"2015","unstructured":"Duc NM, Kim HR, Chung KY (2015) Structural mechanism of G protein activation by G protein-coupled receptor. Eur J Pharmacol 763:214\u2013222. https:\/\/doi.org\/10.1016\/j.ejphar.2015.05.016","journal-title":"Eur J Pharmacol"},{"key":"4548_CR22","unstructured":"Fricke U, Klaus W (1989) Neue Arzneimittel 1988\/89 Fortschritte f\u00fcr die Arzneimitteltherapie?.Wissenschaftliche Verlagsgesellschaft mbH Stuttgart, Stuttgart"},{"key":"4548_CR23","volume-title":"Neue Arzneimittel 1987\/88 Fortschritte f\u00fcr die Arzneimitteltherapie?","author":"U Fricke","year":"1988","unstructured":"Fricke U, Klaus W (1988) Neue Arzneimittel 1987\/88 Fortschritte f\u00fcr die Arzneimitteltherapie? Wissenschaftliche Verlagsgesellschaft mbH Stuttgart, Stuttgart"},{"key":"4548_CR24","volume-title":"Neue Arzneimittel 1989\/90 Fortschritte f\u00fcr die Arzneimitteltherapie?","author":"U Fricke","year":"1990","unstructured":"Fricke U, Klaus W (1990) Neue Arzneimittel 1989\/90 Fortschritte f\u00fcr die Arzneimitteltherapie? Wissenschaftliche Verlagsgesellschaft mbH Stuttgart, Stuttgart"},{"key":"4548_CR25","volume-title":"Neue Arzneimittel 1990\/91 Fortschritte f\u00fcr die Arzneimitteltherapie?","author":"U Fricke","year":"1991","unstructured":"Fricke U, Klaus W (1991) Neue Arzneimittel 1990\/91 Fortschritte f\u00fcr die Arzneimitteltherapie? Wissenschaftliche Verlagsgesellschaft mbH Stuttgart, Stuttgart"},{"key":"4548_CR26","volume-title":"Neue Arzneimittel 1991\/92 Fortschritte f\u00fcr die Arzneimitteltherapie?","author":"U Fricke","year":"1992","unstructured":"Fricke U, Klaus W (1992) Neue Arzneimittel 1991\/92 Fortschritte f\u00fcr die Arzneimitteltherapie? Wissenschaftliche Verlagsgesellschaft mbH Stuttgart, Stuttgart"},{"key":"4548_CR27","volume-title":"Neue Arzneimittel 1993","author":"U Fricke","year":"1994","unstructured":"Fricke U, Klaus W (1994) Neue Arzneimittel 1993. Wissenschaftliche Verlagsgesellschaft mbH Stuttgart, Stuttgart"},{"key":"4548_CR28","volume-title":"Neue Arzneimittel 1994","author":"U Fricke","year":"1995","unstructured":"Fricke U, Klaus W (1995) Neue Arzneimittel 1994. Wissenschaftliche Verlagsgesellschaft mbH Stuttgart, Stuttgart"},{"key":"4548_CR29","volume-title":"Neue Arzneimittel 1995","author":"U Fricke","year":"1997","unstructured":"Fricke U, Klaus W (1997) Neue Arzneimittel 1995. Wissenschaftliche Verlagsgesellschaft mbH Stuttgart, Stuttgart"},{"key":"4548_CR30","volume-title":"Neue Arzneimittel 1996","author":"U Fricke","year":"1999","unstructured":"Fricke U, Klaus W (1999) Neue Arzneimittel 1996. Wissenschaftliche Verlagsgesellschaft mbH Stuttgart, Stuttgart"},{"key":"4548_CR31","volume-title":"Neue Arzneimittel Fakten und Bewertungen von 1996 bis 1998 zugelassenen Arzneimitteln","author":"U Fricke","year":"2000","unstructured":"Fricke U, Klaus W (2000) Neue Arzneimittel Fakten und Bewertungen von 1996 bis 1998 zugelassenen Arzneimitteln. Wissenschaftliche Verlagsgesellschaft mbH Stuttgart, Stuttgart"},{"key":"4548_CR32","doi-asserted-by":"publisher","unstructured":"Geisslinger, G., Menzel, S., Gudermann, T., Hinz, B., Ruth, P., and Mutschler, E. (2020). Mutschler drug effects. 11th, completely revised edition. (Stuttgart: Wissenschaftliche Verlagsgesellschaft). https:\/\/doi.org\/10.52778\/9783804740549.","DOI":"10.52778\/9783804740549"},{"key":"4548_CR33","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1038\/nrm3933","volume":"16","author":"E Ghosh","year":"2015","unstructured":"Ghosh E, Kumari P, Jaiman D, Shukla AK (2015) Methodological advances: the unsung heroes of the GPCR structural revolution. Nat Rev Mol Cell Biol 16:69\u201381. https:\/\/doi.org\/10.1038\/nrm3933","journal-title":"Nat Rev Mol Cell Biol"},{"key":"4548_CR34","doi-asserted-by":"publisher","first-page":"3071","DOI":"10.2174\/138161210793292474","volume":"16","author":"CW Gruber","year":"2010","unstructured":"Gruber CW, Muttenthaler M, Freissmuth M (2010) Ligand-based peptide design and combinatorial peptide libraries to target G protein-coupled receptors. Curr Pharm des 16:3071\u20133088. https:\/\/doi.org\/10.2174\/138161210793292474","journal-title":"Curr Pharm des"},{"key":"4548_CR35","unstructured":"Gruber, C. (2019). Drug development: Peptides from nature as molecular messengers for cell communication. https:\/\/www.meduniwien.ac.at\/web\/ueber-uns\/news\/detailseite\/2019\/news-im-dezember-2020\/peptidforschung\/, last accessed 23.09.2024."},{"key":"4548_CR36","doi-asserted-by":"publisher","first-page":"C583","DOI":"10.1152\/ajpcell.00464.2021","volume":"323","author":"S Guo","year":"2022","unstructured":"Guo S, Zhao T, Yun Y, Xie X (2022) Recent progress in assays for GPCR drug discovery. Am J Physiol Cell Physiol 323:C583\u2013C594. https:\/\/doi.org\/10.1152\/ajpcell.00464.2021","journal-title":"Am J Physiol Cell Physiol"},{"key":"4548_CR37","doi-asserted-by":"publisher","first-page":"829","DOI":"10.1038\/nrd.2017.178","volume":"16","author":"AS Hauser","year":"2017","unstructured":"Hauser AS, Attwood MM, Rask-Andersen M, Schi\u00f6th HB, Gloriam DE (2017) Trends in GPCR drug discovery: new agents, targets and indications. Nat Rev Drug Discov 16:829\u2013842. https:\/\/doi.org\/10.1038\/nrd.2017.178","journal-title":"Nat Rev Drug Discov"},{"key":"4548_CR38","doi-asserted-by":"publisher","first-page":"727","DOI":"10.1038\/nrd892","volume":"1","author":"AL Hopkins","year":"2002","unstructured":"Hopkins AL, Groom CR (2002) The druggable genome. Nat Rev Drug Discov 1:727\u2013730. https:\/\/doi.org\/10.1038\/nrd892","journal-title":"Nat Rev Drug Discov"},{"key":"4548_CR39","doi-asserted-by":"publisher","unstructured":"Interview with Michael Hanson. Nat Rev Drug Discov 15, 80 (2016). https:\/\/doi.org\/10.1038\/nrd.2016.12, https:\/\/www.nature.com\/articles\/nrd.2016.12#citeas, last accessed 23.09.2024","DOI":"10.1038\/nrd.2016.12"},{"key":"4548_CR40","doi-asserted-by":"publisher","first-page":"318","DOI":"10.1016\/j.tibs.2005.04.001","volume":"30","author":"WW Ja","year":"2005","unstructured":"Ja WW, Roberts RW (2005) G-protein-directed ligand discovery with peptide combinatorial libraries. Trends Biochem Sci 30:318\u2013324. https:\/\/doi.org\/10.1016\/j.tibs.2005.04.001","journal-title":"Trends Biochem Sci"},{"key":"4548_CR41","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1016\/j.tips.2011.09.003","volume":"33","author":"V Katritch","year":"2012","unstructured":"Katritch V, Cherezov V, Stevens RC (2012) Diversity and modularity of G protein-coupled receptor structures. Trends Pharmacol Sci 33:17\u201327. https:\/\/doi.org\/10.1016\/j.tips.2011.09.003","journal-title":"Trends Pharmacol Sci"},{"key":"4548_CR42","doi-asserted-by":"publisher","first-page":"839","DOI":"10.1007\/s00210-021-02085-3","volume":"394","author":"G Kayki-Mutlu","year":"2021","unstructured":"Kayki-Mutlu G, Michel MC (2021) A year in pharmacology: new drugs approved by the US Food and Drug Administration in 2020. Naunyn Schmiedebergs Arch Pharmacol 394:839\u2013852. https:\/\/doi.org\/10.1007\/s00210-021-02085-3","journal-title":"Naunyn Schmiedebergs Arch Pharmacol"},{"key":"4548_CR43","doi-asserted-by":"publisher","first-page":"867","DOI":"10.1007\/s00210-022-02250-2","volume":"395","author":"G Kayki-Mutlu","year":"2022","unstructured":"Kayki-Mutlu G, Aksoyalp ZS, Wojnowski L, Michel MC (2022) A year in pharmacology: new drugs approved by the US food and drug administration in 2021. Naunyn Schmiedebergs Arch Pharmacol 395:867\u2013885. https:\/\/doi.org\/10.1007\/s00210-022-02250-2","journal-title":"Naunyn Schmiedebergs Arch Pharmacol"},{"key":"4548_CR44","doi-asserted-by":"publisher","first-page":"1619","DOI":"10.1007\/s00210-023-02465-x","volume":"396","author":"G Kayki-Mutlu","year":"2023","unstructured":"Kayki-Mutlu G, Aksoyalp ZS, Wojnowski L, Michel MC (2023) A year in pharmacology: new drugs approved by the US Food and Drug Administration in 2022. Naunyn Schmiedebergs Arch Pharmacol 396:1619\u20131632. https:\/\/doi.org\/10.1007\/s00210-023-02465-x","journal-title":"Naunyn Schmiedebergs Arch Pharmacol"},{"key":"4548_CR45","doi-asserted-by":"publisher","first-page":"2949","DOI":"10.1007\/s00210-024-03063-1","volume":"397","author":"G Kayki-Mutlu","year":"2024","unstructured":"Kayki-Mutlu G, Aksoyalp ZS, Wojnowski L, Michel MC (2024) A year in pharmacology: new drugs approved by the US Food and Drug Administration in 2023. Naunyn Schmiedebergs Arch Pharmacol 397:2949\u20132970. https:\/\/doi.org\/10.1007\/s00210-024-03063-1","journal-title":"Naunyn Schmiedebergs Arch Pharmacol"},{"issue":"10","key":"4548_CR46","doi-asserted-by":"publisher","DOI":"10.3390\/biom10101445","volume":"10","author":"T Kimura","year":"2020","unstructured":"Kimura T, Pydi SP, Pham J, Tanaka N (2020) Metabolic functions of G protein-coupled receptors in hepatocytes-potential applications for diabetes and NAFLD. Biomolecules 10(10):1445. https:\/\/doi.org\/10.3390\/biom10101445","journal-title":"Biomolecules"},{"key":"4548_CR47","doi-asserted-by":"publisher","first-page":"928","DOI":"10.1002\/1439-7633(20021004)3:10","volume":"3","author":"T Klabunde","year":"2002","unstructured":"Klabunde T, Hessler G (2002) Drug design strategies for targeting G-protein-coupled receptors. ChemBioChem 3:928\u2013944. https:\/\/doi.org\/10.1002\/1439-7633(20021004)3:10","journal-title":"ChemBioChem"},{"key":"4548_CR48","doi-asserted-by":"publisher","first-page":"277","DOI":"10.1093\/jmicro\/dfaa035","volume":"69","author":"Y Kobayashi","year":"2020","unstructured":"Kobayashi Y, Hamamoto A, Saito Y (2020) Analysis of ciliary status via G-protein-coupled receptors localized on primary cilia. Microscopy (Oxf) 69:277\u2013285. https:\/\/doi.org\/10.1093\/jmicro\/dfaa035","journal-title":"Microscopy (Oxf)"},{"key":"4548_CR49","doi-asserted-by":"publisher","first-page":"1085","DOI":"10.1038\/s41586-023-06169-3","volume":"618","author":"K Kobayashi","year":"2023","unstructured":"Kobayashi K, Kawakami K, Kusakizako T, Tomita A, Nishimura M, Sawada K, Okamoto HH, Hiratsuka S, Nakamura G, Kuwabara R, Noda H, Muramatsu H, Shimizu M, Taguchi T, Inoue A, Murata T, Nureki O (2023) Class B1 GPCR activation by an intracellular agonist. Nature 618:1085\u20131093. https:\/\/doi.org\/10.1038\/s41586-023-06169-3","journal-title":"Nature"},{"key":"4548_CR50","doi-asserted-by":"publisher","first-page":"1163","DOI":"10.1038\/s41467-017-01340-7","volume":"8","author":"M Kono","year":"2017","unstructured":"Kono M, Conlon EG, Lux SY, Yanagida K, Hla T, Proia RL (2017) Bioluminescence imaging of G protein-coupled receptor activation in living mice. Nat Commun 8:1163. https:\/\/doi.org\/10.1038\/s41467-017-01340-7","journal-title":"Nat Commun"},{"key":"4548_CR51","doi-asserted-by":"publisher","unstructured":"Kooistra, A.J., Mordalski, S., P\u00e1ndy-Szekeres, G., Esguerra, M., Mamyrbekov, A., Munk, C., Keser\u0171, G.,M., and Gloriam, D.E. (2021). GPCRdb in 2021: integrating GPCR sequence, structure and function. Nucleic Acids Res. 49, D335-D343. https:\/\/doi.org\/10.1093\/nar\/gkaa1080.","DOI":"10.1093\/nar\/gkaa1080"},{"key":"4548_CR52","doi-asserted-by":"publisher","first-page":"149","DOI":"10.1007\/978-1-0716-1221-7_10","volume":"2268","author":"C Laschet","year":"2021","unstructured":"Laschet C, Hanson J (2021) Nanoluciferase-Based Complementation Assay to Detect GPCR-G Protein Interaction. Methods Mol Biol 2268:149\u2013157. https:\/\/doi.org\/10.1007\/978-1-0716-1221-7_10","journal-title":"Methods Mol Biol"},{"key":"4548_CR53","doi-asserted-by":"publisher","first-page":"479","DOI":"10.1124\/dmd.123.001430","volume":"52","author":"BD Latham","year":"2024","unstructured":"Latham BD, Geffert RM, Jackson KD (2024) Kinase Inhibitors FDA Approved 2018\u20132023: Drug Targets, Metabolic Pathways, and Drug-Induced Toxicities. Drug Metab Dispos 52:479\u2013492. https:\/\/doi.org\/10.1124\/dmd.123.001430","journal-title":"Drug Metab Dispos"},{"key":"4548_CR54","doi-asserted-by":"publisher","first-page":"5013","DOI":"10.1021\/acs.jmedchem.9b01452","volume":"63","author":"J Li","year":"2020","unstructured":"Li J, Ge Y, Huang J, Str\u00f8mgaard K, Zhang X, Xiong X (2020) Heterotrimeric G proteins as therapeutic targets in drug discovery. J Med Chem 63:5013\u20135030. https:\/\/doi.org\/10.1021\/acs.jmedchem.9b01452","journal-title":"J Med Chem"},{"key":"4548_CR55","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1016\/j.bcp.2016.02.010","volume":"114","author":"R Liu","year":"2016","unstructured":"Liu R, Wong W, IJzerman AP (2016) Human G protein-coupled receptor studies in Saccharomyces cerevisiae. Biochem Pharmacol 114:103\u2013115. https:\/\/doi.org\/10.1016\/j.bcp.2016.02.010","journal-title":"Biochem Pharmacol"},{"key":"4548_CR56","doi-asserted-by":"publisher","first-page":"458","DOI":"10.1038\/s41573-025-01139-y","volume":"24","author":"JS Lorente","year":"2025","unstructured":"Lorente JS, Sokolov AV, Ferguson G, Schi\u00f6th HB, Hauser AS, Gloriam DE (2025) GPCR drug discovery: new agents, targets and indications. Nat Rev Drug Discov 24:458\u2013479. https:\/\/doi.org\/10.1038\/s41573-025-01139-y","journal-title":"Nat Rev Drug Discov"},{"key":"4548_CR57","volume-title":"Arzneiverordnungs-Report 2021","author":"W Ludwig","year":"2022","unstructured":"Ludwig W, M\u00fchlbauer B, Seifert R (2022) Arzneiverordnungs-Report 2021. Springer, Berlin\/Heidelberg"},{"key":"4548_CR58","volume-title":"Arzneiverordnungs-Report 2022","author":"W Ludwig","year":"2023","unstructured":"Ludwig W, M\u00fchlbauer B, Seifert R (2023) Arzneiverordnungs-Report 2022. Springer, Berlin\/Heidelberg"},{"key":"4548_CR59","volume-title":"Arzneiverordnungs-Report 2023","author":"W Ludwig","year":"2024","unstructured":"Ludwig W, M\u00fchlbauer B, Seifert R (2024) Arzneiverordnungs-Report 2023. Springer, Berlin\/Heidelberg"},{"key":"4548_CR60","doi-asserted-by":"publisher","DOI":"10.1007\/978-3-662-70594-0","volume-title":"Arzneiverordnungs-Report 2024","author":"W Ludwig","year":"2025","unstructured":"Ludwig W, M\u00fchlbauer B, Seifert R (2025) Arzneiverordnungs-Report 2024. Springer, Berlin\/Heidelberg"},{"key":"4548_CR61","doi-asserted-by":"publisher","first-page":"571","DOI":"10.1038\/nrd884","volume":"1","author":"P Ma","year":"2002","unstructured":"Ma P, Zemmel R (2002) Value of novelty? Nat Rev Drug Discov 1:571\u2013572. https:\/\/doi.org\/10.1038\/nrd884","journal-title":"Nat Rev Drug Discov"},{"key":"4548_CR62","doi-asserted-by":"publisher","DOI":"10.1016\/j.drudis.2023.103848","volume":"29","author":"S Majumdar","year":"2024","unstructured":"Majumdar S, Chiu Y, Pickett JE, Roth BL (2024) Illuminating the understudied GPCR-ome. Drug Discov Today 29:103848. https:\/\/doi.org\/10.1016\/j.drudis.2023.103848","journal-title":"Drug Discov Today"},{"key":"4548_CR63","doi-asserted-by":"publisher","first-page":"534","DOI":"10.1038\/s41380-021-01040-1","volume":"27","author":"I Mantas","year":"2022","unstructured":"Mantas I, Saarinen M, Xu ZD, Svenningsson P (2022) Update on GPCR-based targets for the development of novel antidepressants. Mol Psychiatry 27:534\u2013558. https:\/\/doi.org\/10.1038\/s41380-021-01040-1","journal-title":"Mol Psychiatry"},{"key":"4548_CR64","doi-asserted-by":"publisher","first-page":"7474","DOI":"10.1074\/jbc.H118.002879","volume":"293","author":"KA Martemyanov","year":"2018","unstructured":"Martemyanov KA, Garcia-Marcos M (2018) Making useful gadgets with miniaturized G proteins. J Biol Chem 293:7474\u20137475. https:\/\/doi.org\/10.1074\/jbc.H118.002879","journal-title":"J Biol Chem"},{"key":"4548_CR65","doi-asserted-by":"publisher","first-page":"566","DOI":"10.1016\/j.tibtech.2012.07.004","volume":"30","author":"SAM Martins","year":"2012","unstructured":"Martins SAM, Trabuco JRC, Monteiro GA, Chu V, Conde JP, Prazeres DMF (2012) Towards the miniaturization of GPCR-based live-cell screening assays. Trends Biotechnol 30:566\u2013574. https:\/\/doi.org\/10.1016\/j.tibtech.2012.07.004","journal-title":"Trends Biotechnol"},{"key":"4548_CR66","doi-asserted-by":"publisher","first-page":"3664","DOI":"10.1038\/s41467-022-31357-6","volume":"13","author":"K Miettinen","year":"2022","unstructured":"Miettinen K, Leelahakorn N, Almeida A, Zhao Y, Hansen LR, Nikolajsen IE, Andersen JB, Givskov M, Staerk D, Bak S, Kampranis SC (2022) A GPCR-based yeast biosensor for biomedical, biotechnological, and point-of-use cannabinoid determination. Nat Commun 13:3664. https:\/\/doi.org\/10.1038\/s41467-022-31357-6","journal-title":"Nat Commun"},{"key":"4548_CR67","doi-asserted-by":"publisher","first-page":"488","DOI":"10.1017\/jme.2024.105","volume":"52","author":"E Nussli","year":"2024","unstructured":"Nussli E, Serra-Burriel M, Vokinger KN (2024) Comparative analysis of drug shortages in the US and Germany (2016\u20132023). J Law Med Ethics 52:488\u2013497. https:\/\/doi.org\/10.1017\/jme.2024.105","journal-title":"J Law Med Ethics"},{"key":"4548_CR68","doi-asserted-by":"publisher","first-page":"20857","DOI":"10.1038\/s41598-023-47877-0","volume":"13","author":"M Oron-Herman","year":"2023","unstructured":"Oron-Herman M, Kirmayer D, Lupp A, Schulz S, Kostenich G, Afargan M (2023) Expression prevalence and dynamics of GPCR somatostatin receptors 2 and 3 as cancer biomarkers beyond NET: a paired immunohistochemistry approach. Sci Rep 13:20857. https:\/\/doi.org\/10.1038\/s41598-023-47877-0","journal-title":"Sci Rep"},{"key":"4548_CR69","doi-asserted-by":"publisher","first-page":"993","DOI":"10.1038\/nrd2199","volume":"5","author":"JP Overington","year":"2006","unstructured":"Overington JP, Al-Lazikani B, Hopkins AL (2006) How many drug targets are there? Nat Rev Drug Discov 5:993\u2013996. https:\/\/doi.org\/10.1038\/nrd2199","journal-title":"Nat Rev Drug Discov"},{"key":"4548_CR70","doi-asserted-by":"publisher","first-page":"1553","DOI":"10.1111\/bph.16337","volume":"181","author":"A Papapetropoulos","year":"2024","unstructured":"Papapetropoulos A, Topouzis S, Alexander SPH, Cortese-Krott M, Kendall DA, Martemyanov KA, Mauro C, Nagercoil N, Panettieri RAJ, Patel HH, Schulz R, Stefanska B, Stephens GJ, Teixeira MM, Vergnolle N, Wang X, Ferdinandy P (2024) Novel drugs approved by the EMA, the FDA, and the MHRA in 2023: a year in review. Br J Pharmacol 181:1553\u20131575. https:\/\/doi.org\/10.1111\/bph.16337","journal-title":"Br J Pharmacol"},{"key":"4548_CR71","doi-asserted-by":"publisher","DOI":"10.1016\/j.pharmthera.2020.107527","volume":"211","author":"MV Perini","year":"2020","unstructured":"Perini MV, Dmello RS, Nero TL, Chand AL (2020) Evaluating the benefits of renin-angiotensin system inhibitors as cancer treatments. Pharmacol Ther 211:107527. https:\/\/doi.org\/10.1016\/j.pharmthera.2020.107527","journal-title":"Pharmacol Ther"},{"key":"4548_CR72","doi-asserted-by":"publisher","DOI":"10.1016\/j.bcp.2022.115115","volume":"202","author":"NBC Piper","year":"2022","unstructured":"Piper NBC, Whitfield EA, Stewart GD, Xu X, Furness SGB (2022) Targeting appetite and satiety in diabetes and obesity, via G protein-coupled receptors. Biochem Pharmacol 202:115115. https:\/\/doi.org\/10.1016\/j.bcp.2022.115115","journal-title":"Biochem Pharmacol"},{"key":"4548_CR73","doi-asserted-by":"publisher","first-page":"579","DOI":"10.1038\/nrd3478","volume":"10","author":"M Rask-Andersen","year":"2011","unstructured":"Rask-Andersen M, Alm\u00e9n MS, Schi\u00f6th HB (2011) Trends in the exploitation of novel drug targets. Nat Rev Drug Discov 10:579\u2013590. https:\/\/doi.org\/10.1038\/nrd3478","journal-title":"Nat Rev Drug Discov"},{"key":"4548_CR74","doi-asserted-by":"publisher","unstructured":"Rassow, J., Netzker, R., Hauser, K., and Deutzmann, R. (2022). Biochemistry. 5th, completely revised edition. (Stuttgart: Thieme). https:\/\/doi.org\/10.1055\/b0000425.","DOI":"10.1055\/b0000425"},{"key":"4548_CR75","doi-asserted-by":"publisher","first-page":"2192","DOI":"10.1016\/j.drudis.2019.09.003","volume":"24","author":"R Ribeiro-Oliveira","year":"2019","unstructured":"Ribeiro-Oliveira R, Vojtek M, Gon\u00e7alves-Monteiro S, Vieira-Rocha MS, Sousa JB, Gon\u00e7alves J, Diniz C (2019) Nuclear G-protein-coupled receptors as putative novel pharmacological targets. Drug Discov Today 24:2192\u20132201. https:\/\/doi.org\/10.1016\/j.drudis.2019.09.003","journal-title":"Drug Discov Today"},{"key":"4548_CR76","doi-asserted-by":"publisher","first-page":"579","DOI":"10.1016\/j.tips.2015.05.009","volume":"36","author":"EV Romanova","year":"2015","unstructured":"Romanova EV, Sweedler JV (2015) Peptidomics for the discovery and characterization of neuropeptides and hormones. Trends Pharmacol Sci 36:579\u2013586. https:\/\/doi.org\/10.1016\/j.tips.2015.05.009","journal-title":"Trends Pharmacol Sci"},{"key":"4548_CR77","doi-asserted-by":"publisher","first-page":"19471","DOI":"10.1074\/jbc.R115.654764","volume":"290","author":"BL Roth","year":"2015","unstructured":"Roth BL, Kroeze WK (2015) Integrated approaches for genome-wide interrogation of the druggable non-olfactory G protein-coupled receptor superfamily. J Biol Chem 290:19471\u201319477. https:\/\/doi.org\/10.1074\/jbc.R115.654764","journal-title":"J Biol Chem"},{"key":"4548_CR78","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1038\/nrd.2016.230","volume":"16","author":"R Santos","year":"2017","unstructured":"Santos R, Ursu O, Gaulton A, Bento AP, Donadi RS, Bologa CG, Karlsson A, Al-Lazikani B, Hersey A, Oprea TI, Overington JP (2017) A comprehensive map of molecular drug targets. Nat Rev Drug Discov 16:19\u201334. https:\/\/doi.org\/10.1038\/nrd.2016.230","journal-title":"Nat Rev Drug Discov"},{"key":"4548_CR79","unstructured":"Schihada, H. (2021). Novel optical methods to monitor G-protein-coupled receptor activation in microtiter plates; Neue optische Methoden zur Messung der Aktivierung von G-Protein-gekoppelten Rezeptoren in Mikrotiter-Platten, https:\/\/opus.bibliothek.uni-wuerzburg.de\/frontdoor\/index\/index\/docId\/17541, last accessed 23.09.2024."},{"key":"4548_CR80","doi-asserted-by":"publisher","first-page":"C17","DOI":"10.1152\/ajpcell.00397.2022","volume":"325","author":"GP Schmitz","year":"2023","unstructured":"Schmitz GP, Roth BL (2023) G protein-coupled receptors as targets for transformative neuropsychiatric therapeutics. Am J Physiol Cell Physiol 325:C17\u2013C28. https:\/\/doi.org\/10.1152\/ajpcell.00397.2022","journal-title":"Am J Physiol Cell Physiol"},{"key":"4548_CR81","doi-asserted-by":"publisher","first-page":"945","DOI":"10.1038\/s41586-023-05802-5","volume":"615","author":"N Scholz","year":"2023","unstructured":"Scholz N, Dahse A, Kemkemer M, Bormann A, Auger GM, Vieira Contreras F, Ernst LF, Staake H, K\u00f6rner MB, Buhlan M, Meyer-M\u00f6lck A, Chung YK, Blanco-Redondo B, Klose F, Jarboui MA, Ljaschenko D, Bigl M, Langenhan T (2023) Molecular sensing of mechano- and ligand-dependent adhesion GPCR dissociation. Nature 615:945\u2013953. https:\/\/doi.org\/10.1038\/s41586-023-05802-5","journal-title":"Nature"},{"key":"4548_CR82","doi-asserted-by":"publisher","first-page":"4728","DOI":"10.1038\/s41467-022-32390-1","volume":"13","author":"R Schulz","year":"2022","unstructured":"Schulz R, Korkut-Demirba\u015f M, Venturino A, Colombo G, Siegert S (2022) Chimeric GPCRs mimic distinct signaling pathways and modulate microglia responses. Nat Commun 13:4728. https:\/\/doi.org\/10.1038\/s41467-022-32390-1","journal-title":"Nat Commun"},{"key":"4548_CR83","unstructured":"Schwabe U, Ludwig W, Arzneiverordnungs-Report (2020): Aktuelle Daten, Kosten, Trends und Kommentare. Springer, Berlin\/Heidelberg"},{"key":"4548_CR84","doi-asserted-by":"crossref","unstructured":"Schwabe U, Paffrath D, Ludwig W, Klauber J Arzneiverordnungs-Report (2017): aktuelle Daten, Kosten, Trends und Kommentare. Springer, Berlin\/Heidelberg","DOI":"10.1007\/978-3-662-54630-7"},{"key":"4548_CR85","doi-asserted-by":"crossref","unstructured":"Schwabe U, Paffrath D, Ludwig W, Klauber J Arzneiverordnungs-Report (2018): aktuelle Daten, Kosten, Trends und Kommentare. Springer, Berlin\/Heidelberg","DOI":"10.1007\/978-3-662-54630-7"},{"key":"4548_CR86","unstructured":"Schwabe U, Paffrath D, Ludwig W, Klauber J Arzneiverordnungs-Report (2019): aktuelle Daten, Kosten, Trends und Kommentare. Springer, Berlin\/Heidelberg"},{"key":"4548_CR87","unstructured":"Schwabe U, Paffrath D Arzneiverordnungs-Report (1998): Aktuelle Daten, Kosten, Trends und Kommentare. Springer Berlin\/Heidelberg"},{"key":"4548_CR88","unstructured":"Schwabe U, Paffrath D Arzneiverordnungs-Report (1999): Aktuelle Daten, Kosten, Trends und Kommentare. Springer Berlin\/Heidelberg"},{"key":"4548_CR89","doi-asserted-by":"crossref","unstructured":"Schwabe U, Paffrath D Arzneiverordnungs-Report (2000): Aktuelle Daten, Kosten, Trends und Kommentare. Springer Berlin\/Heidelberg","DOI":"10.1007\/978-3-642-57215-9"},{"key":"4548_CR90","doi-asserted-by":"crossref","unstructured":"Schwabe U, Paffrath D Arzneiverordnungs-Report (2001): Aktuelle Daten, Kosten, Trends und Kommentare. Springer Berlin\/Heidelberg","DOI":"10.1007\/978-3-642-56832-9"},{"key":"4548_CR91","doi-asserted-by":"crossref","unstructured":"Schwabe U, Paffrath D Arzneiverordnungs-Report (2002): Aktuelle Daten, Kosten, Trends und Kommentare. Springer Berlin\/Heidelberg","DOI":"10.1007\/978-3-642-56832-9"},{"key":"4548_CR92","doi-asserted-by":"crossref","unstructured":"Schwabe U, Paffrath D Arzneiverordnungs-Report (2003): Aktuelle Daten, Kosten, Trends und Kommentare. Springer Berlin\/Heidelberg","DOI":"10.1007\/978-3-662-11173-4"},{"key":"4548_CR93","doi-asserted-by":"crossref","unstructured":"Schwabe U, Paffrath D Arzneiverordnungs-Report (2004): Aktuelle Daten, Kosten, Trends und Kommentare. Springer Berlin\/Heidelberg","DOI":"10.1007\/978-3-642-18512-0"},{"key":"4548_CR94","unstructured":"Schwabe U, Paffrath D Arzneiverordnungs-Report (2006): Aktuelle Daten, Kosten, Trends und Kommentare. Springer Berlin\/Heidelberg"},{"key":"4548_CR95","unstructured":"Schwabe U, Paffrath D Arzneiverordnungs-Report (2007): Aktuelle Daten, Kosten, Trends und Kommentare. Springer Berlin\/Heidelberg"},{"key":"4548_CR96","unstructured":"Schwabe U, Paffrath D Arzneiverordnungs-Report (2007): Aktuelle Daten, Kosten, Trends und Kommentare. Springer Berlin\/Heidelberg"},{"key":"4548_CR97","doi-asserted-by":"crossref","unstructured":"Schwabe U, Paffrath D Arzneiverordnungs-Report (2010a): Aktuelle Daten, Kosten, Trends und Kommentare. Springer Berlin\/Heidelberg","DOI":"10.1007\/978-3-642-13380-0"},{"key":"4548_CR98","doi-asserted-by":"crossref","unstructured":"Schwabe U, Paffrath D Arzneiverordnungs-Report (2010b): Aktuelle Daten, Kosten, Trends und Kommentare. Springer Berlin\/Heidelberg","DOI":"10.1007\/978-3-642-13380-0"},{"key":"4548_CR99","doi-asserted-by":"crossref","unstructured":"Schwabe U, Paffrath D Arzneiverordnungs-Report (2011a): Aktuelle Daten, Kosten, Trends und Kommentare. Springer Berlin\/Heidelberg","DOI":"10.1007\/978-3-642-13380-0"},{"key":"4548_CR100","doi-asserted-by":"crossref","unstructured":"Schwabe U, Paffrath D Arzneiverordnungs-Report (2011b): Aktuelle Daten, Kosten, Trends und Kommentare. Springer Berlin\/Heidelberg","DOI":"10.1007\/978-3-642-13380-0"},{"key":"4548_CR101","unstructured":"Schwabe U, Paffrath D Arzneiverordnungs-Report (2012): Aktuelle Daten, Kosten, Trends und Kommentare. Springer Berlin\/Heidelberg"},{"key":"4548_CR102","unstructured":"Schwabe U, Paffrath D Arzneiverordnungs-Report (2013): Aktuelle Daten, Kosten, Trends und Kommentare. Springer Berlin\/Heidelberg"},{"key":"4548_CR103","unstructured":"Schwabe U, Paffrath D Arzneiverordnungs-Report (2014): Aktuelle Daten, Kosten, Trends und Kommentare. Springer Berlin\/Heidelberg"},{"key":"4548_CR104","unstructured":"Schwabe U, Paffrath D Arzneiverordnungs-Report (2015): Aktuelle Daten, Kosten, Trends und Kommentare. Springer Berlin\/Heidelberg"},{"key":"4548_CR105","doi-asserted-by":"crossref","unstructured":"Schwabe U, Paffrath D Arzneiverordnungs-Report (2016): Aktuelle Daten, Kosten, Trends und Kommentare. Springer Berlin\/Heidelberg","DOI":"10.1007\/978-3-662-54630-7"},{"key":"4548_CR106","doi-asserted-by":"publisher","first-page":"98","DOI":"10.1016\/j.cbpa.2020.04.012","volume":"56","author":"MM Shchepinova","year":"2020","unstructured":"Shchepinova MM, Hanyaloglu AC, Frost GS, Tate EW (2020) Chemical biology of noncanonical G protein-coupled receptor signaling: toward advanced therapeutics. Curr Opin Chem Biol 56:98\u2013110. https:\/\/doi.org\/10.1016\/j.cbpa.2020.04.012","journal-title":"Curr Opin Chem Biol"},{"key":"4548_CR107","doi-asserted-by":"publisher","unstructured":"Simon, E., Ungeth\u00fcm, U., Kuban, R.J., Neumann, U., Ebert, M., and R\u00f6cken, C. https:\/\/doi.org\/10.1055\/s-0028-1089702","DOI":"10.1055\/s-0028-1089702"},{"key":"4548_CR108","doi-asserted-by":"publisher","first-page":"570","DOI":"10.1124\/pr.113.008425","volume":"66","author":"HJ Solinski","year":"2014","unstructured":"Solinski HJ, Gudermann T, Breit A (2014) Pharmacology and signaling of MAS-related G protein-coupled receptors. Pharmacol Rev 66:570\u2013597. https:\/\/doi.org\/10.1124\/pr.113.008425","journal-title":"Pharmacol Rev"},{"key":"4548_CR109","doi-asserted-by":"publisher","first-page":"251","DOI":"10.1124\/mol.117.111062","volume":"93","author":"K Sriram","year":"2018","unstructured":"Sriram K, Insel PA (2018) G protein-coupled receptors as targets for approved drugs: how many targets and how many drugs? Mol Pharmacol 93:251\u2013258. https:\/\/doi.org\/10.1124\/mol.117.111062","journal-title":"Mol Pharmacol"},{"key":"4548_CR110","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1038\/nrd3859","volume":"12","author":"RC Stevens","year":"2013","unstructured":"Stevens RC, Cherezov V, Katritch V, Abagyan R, Kuhn P, Rosen H, W\u00fcthrich K (2013) The GPCR network: a large-scale collaboration to determine human GPCR structure and function. Nat Rev Drug Discov 12:25\u201334. https:\/\/doi.org\/10.1038\/nrd3859","journal-title":"Nat Rev Drug Discov"},{"key":"4548_CR111","doi-asserted-by":"publisher","first-page":"1997","DOI":"10.1038\/s41467-019-09938-9","volume":"10","author":"G Syu","year":"2019","unstructured":"Syu G, Wang S, Ma G, Liu S, Pearce D, Prakash A, Henson B, Weng L, Ghosh D, Ramos P, Eichinger D, Pino I, Dong X, Xiao J, Wang S, Tao N, Kim KS, Desai PJ, Zhu H (2019) Development and application of a high-content virion display human GPCR array. Nat Commun 10:1997. https:\/\/doi.org\/10.1038\/s41467-019-09938-9","journal-title":"Nat Commun"},{"key":"4548_CR112","doi-asserted-by":"publisher","first-page":"363","DOI":"10.1038\/aps.2011.210","volume":"33","author":"X Tang","year":"2012","unstructured":"Tang X, Wang Y, Li D, Luo J, Liu M (2012) Orphan G protein-coupled receptors (GPCRs): biological functions and potential drug targets. Acta Pharmacol Sin 33:363\u2013371. https:\/\/doi.org\/10.1038\/aps.2011.210","journal-title":"Acta Pharmacol Sin"},{"key":"4548_CR113","doi-asserted-by":"publisher","first-page":"34911","DOI":"10.1074\/jbc.274.49.34911","volume":"274","author":"NI Tarasova","year":"1999","unstructured":"Tarasova NI, Rice WG, Michejda CJ (1999) Inhibition of G-protein-coupled receptor function by disruption of transmembrane domain interactions*. J Biol Chem 274:34911\u201334915. https:\/\/doi.org\/10.1074\/jbc.274.49.34911","journal-title":"J Biol Chem"},{"key":"4548_CR114","doi-asserted-by":"publisher","first-page":"1416","DOI":"10.1111\/bph.17458","volume":"182","author":"S Topouzis","year":"2025","unstructured":"Topouzis S, Papapetropoulos A, Alexander SPH, Cortese-Krott M, Kendall DA, Martemyanov K, Mauro C, Nagercoil N, Panettieri RA Jr., Patel HH, Schulz R, Stefanska B, Stephens GJ, Teixeira MM, Vergnolle N, Wang X, Ferdinandy P (2025) Novel drugs approved by the EMA, the FDA and the MHRA in 2024: a year in review. Br J Pharmacol 182:1416\u20131445. https:\/\/doi.org\/10.1111\/bph.17458","journal-title":"Br J Pharmacol"},{"key":"4548_CR115","doi-asserted-by":"publisher","DOI":"10.1016\/j.jmr.2022.107164","volume":"336","author":"T Ueda","year":"2022","unstructured":"Ueda T, Imai S, Shimada I (2022) Function-related dynamics of GPCRs. J Magn Reson 336:107164. https:\/\/doi.org\/10.1016\/j.jmr.2022.107164","journal-title":"J Magn Reson"},{"key":"4548_CR116","unstructured":"University. Marburg, https:\/\/archiv.ub.uni-marburg.de\/ubfind\/Record\/urn:nbn:de:hebis:04-z2020-0530, last accessed 18.09.2024"},{"key":"4548_CR117","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1016\/j.ceb.2013.11.002","volume":"27","author":"NM Urs","year":"2014","unstructured":"Urs NM, Nicholls PJ, Caron MG (2014) Integrated approaches to understanding antipsychotic drug action at GPCRs. Curr Opin Cell Biol 27:56\u201362. https:\/\/doi.org\/10.1016\/j.ceb.2013.11.002","journal-title":"Curr Opin Cell Biol"},{"key":"4548_CR118","doi-asserted-by":"publisher","first-page":"811365","DOI":"10.3389\/fmolb.2022.811365","volume":"9","author":"A Van Baelen","year":"2022","unstructured":"Van Baelen A, Robin P, Kessler P, Ma\u00efga A, Gilles N, Servent D (2022) Structural and Functional Diversity of Animal Toxins Interacting With GPCRs. Front Mol Biosci 9:811365. https:\/\/doi.org\/10.3389\/fmolb.2022.811365","journal-title":"Front Mol Biosci"},{"key":"4548_CR119","doi-asserted-by":"publisher","first-page":"94","DOI":"10.1038\/nrd.2018.13","volume":"17","author":"MT Villanueva","year":"2018","unstructured":"Villanueva MT (2018) Know your GPCR mutations (and target them right). Nat Rev Drug Discov 17:94. https:\/\/doi.org\/10.1038\/nrd.2018.13","journal-title":"Nat Rev Drug Discov"},{"key":"4548_CR120","doi-asserted-by":"publisher","DOI":"10.1016\/j.bcp.2020.114370","volume":"187","author":"X Wang","year":"2021","unstructured":"Wang X, van Westen GJP, Heitman LH, IJzerman AP (2021) G protein-coupled receptors expressed and studied in yeast. The adenosine receptor as a prime example. Biochem Pharmacol 187:114370. https:\/\/doi.org\/10.1016\/j.bcp.2020.114370","journal-title":"Biochem Pharmacol"},{"key":"4548_CR121","doi-asserted-by":"publisher","first-page":"2963","DOI":"10.1111\/bph.15468","volume":"178","author":"LR Watkins","year":"2021","unstructured":"Watkins LR, Orlandi C (2021) In vitro profiling of orphan G protein coupled receptor (GPCR) constitutive activity. Br J Pharmacol 178:2963\u20132975. https:\/\/doi.org\/10.1111\/bph.15468","journal-title":"Br J Pharmacol"},{"issue":"1","key":"4548_CR122","doi-asserted-by":"publisher","DOI":"10.1210\/endocr\/bqab245","volume":"163","author":"J Wess","year":"2022","unstructured":"Wess J (2022) In vivo metabolic roles of G proteins of the Gi family studied with novel mouse models. Endocrinology 163(1):bqab245. https:\/\/doi.org\/10.1210\/endocr\/bqab245","journal-title":"Endocrinology"},{"key":"4548_CR123","unstructured":"Wikipedia.org. G protein-coupled receptors, https:\/\/de.wikipedia.org\/wiki\/G-Protein-gekoppelte_Rezeptoren, last accessed 23.09.2024."},{"key":"4548_CR124","doi-asserted-by":"publisher","first-page":"235","DOI":"10.1016\/s1359-6446(01)02131-6","volume":"7","author":"A Wise","year":"2002","unstructured":"Wise A, Gearing K, Rees S (2002) Target validation of G-protein coupled receptors. Drug Discov Today 7:235\u2013246. https:\/\/doi.org\/10.1016\/s1359-6446(01)02131-6","journal-title":"Drug Discov Today"},{"key":"4548_CR125","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1038\/s41392-023-01427-2","volume":"8","author":"T Wong","year":"2023","unstructured":"Wong T, Li G, Li S, Gao W, Chen G, Gan S, Zhang M, Li H, Wu S, Du Y (2023) G protein-coupled receptors in neurodegenerative diseases and psychiatric disorders. Signal Transduct Target Ther 8:177. https:\/\/doi.org\/10.1038\/s41392-023-01427-2","journal-title":"Signal Transduct Target Ther"},{"key":"4548_CR126","doi-asserted-by":"publisher","first-page":"1752","DOI":"10.1109\/TCBB.2020.3008014","volume":"18","author":"H Wu","year":"2021","unstructured":"Wu H, Ling H, Gao L, Fu Q, Lu W, Ding Y, Jiang M, Li H (2021) Empirical potential energy function toward ab initio folding G protein-coupled receptors. IEEE ACM Trans Comput Biol Bioinform 18:1752\u20131762. https:\/\/doi.org\/10.1109\/TCBB.2020.3008014","journal-title":"IEEE ACM Trans Comput Biol Bioinform"},{"key":"4548_CR127","doi-asserted-by":"publisher","first-page":"210","DOI":"10.1016\/j.copbio.2020.06.004","volume":"64","author":"EA Yasi","year":"2020","unstructured":"Yasi EA, Kruyer NS, Peralta-Yahya P (2020) Advances in G protein-coupled receptor high-throughput screening. Curr Opin Biotechnol 64:210\u2013217. https:\/\/doi.org\/10.1016\/j.copbio.2020.06.004","journal-title":"Curr Opin Biotechnol"}],"container-title":["Naunyn-Schmiedeberg's Archives of Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00210-025-04548-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00210-025-04548-3","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00210-025-04548-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,2]],"date-time":"2026-04-02T03:17:23Z","timestamp":1775099843000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00210-025-04548-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11,6]]},"references-count":127,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2026,2]]}},"alternative-id":["4548"],"URL":"https:\/\/doi.org\/10.1007\/s00210-025-04548-3","relation":{},"ISSN":["0028-1298","1432-1912"],"issn-type":[{"value":"0028-1298","type":"print"},{"value":"1432-1912","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,11,6]]},"assertion":[{"value":"3 December 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 August 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 November 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This work was carried out in accordance with the guidelines of good scientific practice of Hannover Medical School (\n                      \n                      ) and officially registered as a doctoral project for Sophia Schr\u00f6er. Hannover Medical School follows the guidelines of the German Research Foundation (DFG).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics statement"}},{"value":"Not applicable, as publicly available information is used as a data source.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Publication consent"}},{"value":"R.S. is the Editor-in-Chief of Naunyn-Schmiedebergs Archives of Pharmacology and follows the editorial guidelines for editors acting as authors (\n                      \n                      ).","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}